Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas

Background: Cytotoxic chemotherapy remains the main systemic therapy for gastro-oesophageal adenocarcinoma, but resistance to chemotherapy is

[1]  I. Kovalszky,et al.  Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. , 2011, European journal of cancer.

[2]  M. Rahmati-Yamchi,et al.  Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors , 2012, Cytotechnology.

[3]  T. Petit,et al.  Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer , 2010, Breast Cancer Research and Treatment.

[4]  G. Ball,et al.  Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[6]  L. Otvos,et al.  Glioblastoma-derived Leptin Induces Tube Formation and Growth of Endothelial Cells: Comparison with VEGF Effects , 2011, BMC Cancer.

[7]  Ki-Seok Jang,et al.  Leptin Expression Correlates with Favorable Clinicopathologic Phenotype and Better Prognosis in Colorectal Adenocarcinoma , 2009, Annals of Surgical Oncology.

[8]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[9]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[10]  D. Ferry,et al.  A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response , 2007, Clinical Cancer Research.

[11]  R. Hu,et al.  Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer , 2007, Journal of gastroenterology and hepatology.

[12]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[13]  G. Murray,et al.  Characterisation and protein expression profiling of annexins in colorectal cancer , 2007, British Journal of Cancer.

[14]  Z. Halpern,et al.  Development and Characterization of High Affinity Leptins and Leptin Antagonists* , 2010, The Journal of Biological Chemistry.

[15]  A. Gertler,et al.  Leptin-activity blockers: development and potential use in experimental biology and medicine. , 2013, Canadian journal of physiology and pharmacology.

[16]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[17]  W. Ichikawa,et al.  Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. VanSaun.  Molecular Pathways Molecular Pathways : Adiponectin and Leptin Signaling in Cancer , 2013 .

[19]  E. Chiorean.  Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2012 .

[20]  O. Ogunwobi,et al.  Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. , 2006, Endocrinology.

[21]  J. Fraumeni,et al.  A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. , 2008, European journal of cancer.

[22]  J. Ajani,et al.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Petty.  Exclusive rights in gastric cancer genomics , 2012, Gut.

[24]  H. Adami,et al.  A global assessment of the oesophageal adenocarcinoma epidemic , 2012, Gut.

[25]  B. Teh,et al.  Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer , 2012, Gut.

[26]  O. Ogunwobi,et al.  Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture , 2007, Molecular and Cellular Endocrinology.

[27]  Yongmei Yin,et al.  Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  P. Beddy,et al.  Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma , 2010, The British journal of surgery.

[29]  H. Nagawa,et al.  Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. , 2005, Cancer research.

[30]  Xiaofei Xu,et al.  Leptin-mediated regulation of MT1-MMP localization is KIF1B dependent and enhances gastric cancer cell invasion. , 2013, Carcinogenesis.

[31]  C. Barone,et al.  Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? , 2008, The oncologist.

[32]  J. Ahn,et al.  Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[34]  V. Speirs,et al.  A novel cell array technique for high-throughput, cell-based analysis , 2005, In Vitro Cellular & Developmental Biology - Animal.

[35]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[36]  G. Murray,et al.  The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. , 2011, Human pathology.

[37]  T. Funahashi,et al.  High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels , 2006, International journal of cancer.

[38]  A. Tarnawski,et al.  Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. , 2005, Biochemical and biophysical research communications.

[39]  B. Kahn,et al.  Leptin signaling in the central nervous system and the periphery. , 2004, Recent progress in hormone research.

[40]  H. Kim.  Leptin and leptin receptor expression in breast cancer. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.